Jim Simons Apellis Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 372,331 shares of APLS stock, worth $10.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

372,331

Holding current value

$10.9 Million

% of portfolio

0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$28.84 - $41.15 $10.7 Million - $15.3 Million	372,331 New	372,331 $10.7 Million
Q2 2023 Aug 11, 2023	BUY	$76.68 - $93.31 $10.6 Million - $12.9 Million	138,513 New	138,513 $12.6 Million
Q4 2022 Feb 13, 2023	SELL	$43.24 - $61.04 $6.82 Million - $9.63 Million	-157,700 Reduced 45.7%	187,413 $9.69 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $15.4 Million - $24 Million	345,113 New	345,113 $23.6 Million
Q3 2021 Nov 12, 2021	SELL	$31.4 - $69.84 $634,625 - $1.41 Million	-20,211 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$40.9 - $64.9 $14.5 Million - $22.9 Million	-353,302 Reduced 94.59%	20,211 $1.28 Million
Q1 2021 May 13, 2021	BUY	$40.8 - $57.39 $6.41 Million - $9.02 Million	157,200 Added 72.67%	373,513 $16 Million
Q4 2020 Feb 10, 2021	BUY	$30.79 - $57.2 $6.66 Million - $12.4 Million	216,313 New	216,313 $12.4 Million
Q1 2020 May 14, 2020	SELL	$17.91 - $44.33 $349,477 - $865,011	-19,513 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$22.1 - $30.8 $431,237 - $601,000	19,513 New	19,513 $597,000
Q2 2019 Aug 12, 2019	SELL	$18.0 - $25.34 $471,600 - $663,908	-26,200 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$12.81 - $19.82 $335,622 - $519,284	26,200 New	26,200 $511,000

Others Institutions Holding APLS

# of Institutions

303

Shares Held

112M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.23B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account